Press Release
Moffitt Cancer Center launches first-in-nation Venture Studio for Digital Oncology - AccelerOnc Studio, and Unveils Portfolio Companies
HLTH 2025, Las Vegas, NV – AccelerOnc Studio, the nation's first digital oncology venture studio backed by Moffitt Cancer Center, today announced its initial portfolio of companies. The studio aims to transform Moffitt's world-class oncology research and intellectual property into companies that address critical gaps in cancer care.
Decimal.health, a digital health innovation company, will provide operational expertise and strategic guidance to accelerate portfolio company growth and identify new commercialization opportunities within Moffitt's innovation pipeline.
"The launch of AccelerOnc Studio is a significant step in our mission to contribute bold breakthroughs in cancer research and care," said Patrick Hwu, M.D., President and CEO of Moffitt. "This venture studio strengthens our ability to bring Moffitt's expertise and innovations to cancer patients around the world and supports our strategy to lead in a new era where digital technologies and artificial intelligence are transforming how we understand and treat cancer."
Meet the Portfolio
The BlueScrubs – BlueScrubs is creating the world’s first AI Oncologist — designed to ensure that every cancer patient, everywhere, receives guideline-concordant, evidence-based care. With medical knowledge doubling every 73 days and oncology guidelines updating more than 50 times a year, it’s nearly impossible for clinicians to keep pace. For the 80% of cancer patients treated in community settings, this means fewer than half currently receive fully guideline-aligned treatment — leading to uneven outcomes.
Founded by Dr. Gilmer Valdes, Head of Clinical AI at Moffitt Cancer Center and CEO of BlueScrubs, the company is building technology that puts the latest oncology expertise directly in physicians’ hands, empowering them to deliver the best possible care to every patient, in every setting.
ClearOnc Insights by Moffitt – Democratizing access to Moffitt's oncology specialists nationwide. The platform connects patients through employers and payers with expert oncologists who review records and provide evidence-based treatment guidance, removing geographic and complexity barriers to world-class cancer care.
“At AccelerOnc, we’re building a repeatable model for turning clinical insight into commercial impact,” said Kamal Jethwani, MD, MPH, CEO of AccelerOnc Studio. “By combining our venture-building experience with Moffitt’s world-class oncology expertise, we’re not just launching companies — we’re accelerating the path from discovery to patient impact. The strong early momentum, especially The BlueScrubs’ fundraising success, shows that the market is ready for solutions built by oncologists, for oncologists.”
AccelerOnc invites health systems, pharmaceutical partners, and investors to explore collaboration opportunities at HLTH 2025.
About AccelerOnc Studio
AccelerOnc Studio is the first digital oncology venture studio in the United States, backed by Moffitt Cancer Center. The studio identifies unmet clinical needs and commercializes intellectual property from leading health systems and cancer centers, starting with Moffitt Cancer Center.
About Moffitt Cancer Center
Moffitt is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, recognized for scientific excellence, multidisciplinary research, and commitment to cancer prevention and cure.
About Decimal.health
Decimal.health is a digital health innovation firm that provides strategy consulting, venture building, thought leadership, and community development to help health systems, life sciences companies, and digital health innovators bring evidence-based solutions to market. As the venture-building force behind AccelerOnc Studio, and the operational backbone of CancerX, we power some of the most transformative programs in healthcare.
Read on Moffitt Cancer Center.
Media Contact:
Kim Polacek
813-504-9706